Back to top
more

Nevro (NVRO)

(Delayed Data from NYSE)

$11.29 USD

11.29
373,702

+0.14 (1.26%)

Updated May 3, 2024 04:00 PM ET

After-Market: $11.27 -0.02 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Indrajit Bandyopadhyay headshot

4 MedTech Stocks Set to Outpace Q3 Earnings Estimates

by Indrajit Bandyopadhyay

Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.

NextGen Healthcare (NXGN) Q2 Earnings Beat, FY23 View Up

by Zacks Equity Research

NextGen's (NXGN) second-quarter fiscal 2023 results reflect strength in both its revenue sources.

Catalent (CTLT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Q1 earnings are likely to have been driven by robust segmental performances.

Nevro (NVRO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q2 sales.

Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) third-quarter results are likely to reflect continued strength in its Global Industrial segment.

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) third quarter's top line.

Nevro (NVRO) Gains Following FDA Approval for Senza HFX iQ

by Zacks Equity Research

Nevro (NVRO) gets FDA approval for its next-generation SCS system, Senza HFX iQ, for treating chronic back and leg pain.

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Why Is Nevro (NVRO) Down 1% Since Last Earnings Report?

by Zacks Equity Research

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nevro's (NVRO) PDN Therapy Gets Positive Coverage Updates

by Zacks Equity Research

Latest favorable coverage decisions for Nevro's (NVRO) PDN Therapy are expected to serve a wider patient pool.

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.

Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 12.35% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Nevro (NVRO) Stock Falls 19% Despite Q1 Earnings Beat

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.

Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 11.71% and 2.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Nevro (NVRO) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Nevro's (NVRO) PDN Therapy Gets Noridian's Medicare Coverage

by Zacks Equity Research

Latest favorable coverage decision for Nevro's (NVRO) PDN Therapy by Noridian is expected to allow the former to serve a wider patient pool.

Nevro's (NVRO) Q4 Earnings in Line, Revenues Beat Estimates

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.

Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 0% and 0.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong segmental performance.

Here's Why You Should Retain Nevro (NVRO) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Hologic (HOLX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 80.83% and 31.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?